Financiere de Tubize (STU:FTD) Total Current Assets : €0.56 Mil (As of Jun. 2024)

View and export this data going back to 2013. Start your Free Trial

What is Financiere de Tubize Total Current Assets?

Total current assets includes Cash, Cash Equivalents, Marketable Securities, Total Receivables, Total Inventories, and Other Current Assets. Financiere de Tubize's total current assets for the quarter that ended in Jun. 2024 was €0.56 Mil.

Financiere de Tubize Total Current Assets Historical Data

The historical data trend for Financiere de Tubize's Total Current Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Financiere de Tubize Total Current Assets Chart

Financiere de Tubize Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Total Current Assets

Get a 7-Day Free Trial

0.53

1.03

15.93

1.12

0.64

Financiere de Tubize Semi-Annual Data
	Dec14	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23	Jun24
Total Current Assets	Get a 7-Day Free Trial															0.56	1.12	1.65	0.64	0.56

Financiere de Tubize Total Current Assets Calculation

Total Current Assets are the asset that can be converted to cash or used to pay current liabilities within 12 months.

Financiere de Tubize's Total Current Assets for the fiscal year that ended in Dec. 2023 is calculated as

Total Current Assets	=	Cash, Cash Equivalents, Marketable Securities	+	Total Receivables	+	Total Inventories	+	Other Current Assets
	=	0.575	+	0.06	+	0	+	0
	=	0.64

Financiere de Tubize's Total Current Assets for the quarter that ended in Jun. 2024 is calculated as

Total Current Assets	=	Cash, Cash Equivalents, Marketable Securities	+	Total Receivables	+	Total Inventories	+	Other Current Assets
	=	0.503	+	0.058	+	0	+	0
	=	0.56

Total Current Assets is linked to the Current Ratio, which is the result of dividing total current assets by total current liabilities. It is frequently used as an indicator of a company's liquidity, its ability to meet short-term obligations.

Total Current Assets is also linked to Working Capital, Net working capital is calculated as Total Current Assets minus Total Current Liabilities.

Financiere de Tubize (STU:FTD) Total Current Assets Explanation

In Ben Graham's calculation of liquidation value, inventory is only considered worth half of its book value, and accounts receivable is considered worth 75% of its value. Therefore the liquidation value is lower than calculated from total current assets.

Financiere de Tubize's Liquidation Value for the quarter that ended in Jun. 2024 is

	Liquidation value
=	Cash, Cash Equivalents, Marketable Securities	-	Total Liabilities	+	(0.75 * Accounts Receivable)	+	(0.5 * Total Inventories)
=	0.503	-	31.685	+	0.75 * 0	+	0.5 * 0
=	-31.18

Financiere de Tubize Total Current Assets Related Terms

Thank you for viewing the detailed overview of Financiere de Tubize's Total Current Assets provided by GuruFocus.com. Please click on the following links to see related term pages.

Financiere de Tubize Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Financiere de Tubize SA (STU:FTD) » Definitions » Total Current Assets

Comparable Companies

Traded in Other Exchanges

0D53:UK TUB:Belgium

Address

Allee de la Recherche, 60, Brussels, BEL, 1070

Website

https://www.financiere-tubize.be

Financiere de Tubize SA is a holding company that owns a stake in UCB, a biopharmaceutical company. UCB is a global biotechnology company that develops treatments for conditions related to neurology and immunology. UCB generates the vast majority of its revenue in the United States, followed by Europe and other international markets. Most of its sales revenue is derived from its neurology products, followed by its immunology products. The company's strategy focuses on leveraging scientific advances and skills in areas such as genetics, biomarkers, and human biology.

Financiere de Tubize Headlines

No Headlines